The Outcome and Safety of Re-challenge Lutetium-177 PSMA (177Lu-PSMA) Therapy with Low-Dose Docetaxel as a Radiosensitizer—a Promising Combination in Metastatic Castrate-Resistant Prostate Cancer (mCRPC): a Case Report.

Autor: Maharaj, Masha, Heslop, Lucille, Govender, Trisha, Korowlay, Nisaar, Singh, Aviral, Choudhary, Partha, Sathekge, Mike

Publikováno v: Nuclear Medicine & Molecular Imaging; Jun2021, Vol. 55 Issue 3, p136-140, 5p

Exceptional Response of Rare Plasmacytoid Variant Prostate Cancer Post 177 Lu-PSMA Therapy Seen on 68 Ga-PSMA PET/CT.

Autor: Maharaj, Masha, Heslop, Lucille, Govender, Trisha, Korowlay, Nisaar

Publikováno v: Clinical Nuclear Medicine; Feb2023, Vol. 48 Issue 2, pe69-e70, 2p

The Outcome and Safety of Re-challenge Lutetium-177 PSMA ( ¹⁷⁷ Lu-PSMA) Therapy with Low-Dose Docetaxel as a Radiosensitizer-a Promising Combination in Metastatic Castrate-Resistant Prostate Cancer (mCRPC): a Case Report.

Autor: Maharaj M; Department of Nuclear Medicine, Imaging and Therapy Centres of Excellence, Durban, KwaZulu Natal South Africa., Heslop L; Durban Oncology Centre, West Ridge, Durban, South Africa., Govender T; Department of Nuclear Medicine, Imaging and Therapy Centres of Excellence, Durban, KwaZulu Natal South Africa., Korowlay N; Division of Nuclear Medicine, Tygerberg Hospital, Stellenbosch University, Stellenbosch, South Africa., Singh A; Theranostics Center for Molecular Radiotherapy and Molecular Imaging (PET/CT) ENETS Center of Excellence, Zentralklinik Bad Berka GmbH, Bad Berka, Germany., Choudhary P; Department of Nuclear Medicine, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India., Sathekge M; Department of Nuclear Medicine, University of Pretoria & Steve Biko Academic Hospital, Pretoria, South Africa.

Publikováno v: Nuclear medicine and molecular imaging [Nucl Med Mol Imaging] 2021 Jun; Vol. 55 (3), pp. 136-140. Date of Electronic Publication: 2021 Apr 13.